430 related articles for article (PubMed ID: 34824298)
41. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
[TBL] [Abstract][Full Text] [Related]
42. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
[TBL] [Abstract][Full Text] [Related]
43. Diagnosis of Castleman Disease.
Szalat R; Munshi NC
Hematol Oncol Clin North Am; 2018 Feb; 32(1):53-64. PubMed ID: 29157619
[TBL] [Abstract][Full Text] [Related]
44. High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma.
Deloose ST; Smit LA; Pals FT; Kersten MJ; van Noesel CJ; Pals ST
Leukemia; 2005 May; 19(5):851-5. PubMed ID: 15744337
[TBL] [Abstract][Full Text] [Related]
45. TAFRO Syndrome.
Igawa T; Sato Y
Hematol Oncol Clin North Am; 2018 Feb; 32(1):107-118. PubMed ID: 29157612
[TBL] [Abstract][Full Text] [Related]
46. The clinical application of plasma Kaposi sarcoma herpesvirus viral load as a tumour biomarker: results from 704 patients.
Haq IU; Dalla Pria A; Papanastasopoulos P; Stegmann K; Bradshaw D; Nelson M; Bower M
HIV Med; 2016 Jan; 17(1):56-61. PubMed ID: 26111246
[TBL] [Abstract][Full Text] [Related]
47. [Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].
Okamoto S
Rinsho Ketsueki; 2019; 60(9):1205-1211. PubMed ID: 31597845
[TBL] [Abstract][Full Text] [Related]
48. Characteristics of patients admitted to the ICU with Kaposi sarcoma herpesvirus-associated diseases.
Hansen ME; Mangusan R; Lurain K; Odeny T; George J; Lu C; Manion M; Widell A; Ekwede I; Whitby D; Gulley JL; Kadri SS; Elinoff JM; Barochia A; Torabi-Parizi P; Uldrick TS; Yarchoan R; Ramaswami R
AIDS; 2022 Nov; 36(14):1969-1978. PubMed ID: 35848586
[TBL] [Abstract][Full Text] [Related]
49. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.
Uldrick TS; Polizzotto MN; Aleman K; Wyvill KM; Marshall V; Whitby D; Wang V; Pittaluga S; O'Mahony D; Steinberg SM; Little RF; Yarchoan R
Blood; 2014 Dec; 124(24):3544-52. PubMed ID: 25331113
[TBL] [Abstract][Full Text] [Related]
50. Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Thymidine Kinase (ORF21) by X-Box Binding Protein 1.
Wang V; Davis DA; Deleage C; Brands C; Choi HS; Haque M; Yarchoan R
J Virol; 2020 Feb; 94(5):. PubMed ID: 31801863
[TBL] [Abstract][Full Text] [Related]
51. Sequence analysis of Kaposi sarcoma-associated herpesvirus (KSHV) microRNAs in patients with multicentric Castleman disease and KSHV-associated inflammatory cytokine syndrome.
Ray A; Marshall V; Uldrick T; Leighty R; Labo N; Wyvill K; Aleman K; Polizzotto MN; Little RF; Yarchoan R; Whitby D
J Infect Dis; 2012 Jun; 205(11):1665-76. PubMed ID: 22448005
[TBL] [Abstract][Full Text] [Related]
52. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy.
Corbellino M; Bestetti G; Scalamogna C; Calattini S; Galazzi M; Meroni L; Manganaro D; Fasan M; Moroni M; Galli M; Parravicini C
Blood; 2001 Dec; 98(12):3473-5. PubMed ID: 11719390
[TBL] [Abstract][Full Text] [Related]
53. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis.
Wen KW; Damania B
Cancer Lett; 2010 Mar; 289(2):140-50. PubMed ID: 19651473
[TBL] [Abstract][Full Text] [Related]
54. Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma.
Burbelo PD; Issa AT; Ching KH; Wyvill KM; Little RF; Iadarola MJ; Kovacs JA; Yarchoan R
J Infect Dis; 2010 Jun; 201(12):1919-22. PubMed ID: 20443737
[TBL] [Abstract][Full Text] [Related]
55. Adaptive immune responses to Kaposi's sarcoma-associated herpesvirus.
Nalwoga A; Whitby D
Curr Opin Immunol; 2022 Aug; 77():102230. PubMed ID: 35810680
[TBL] [Abstract][Full Text] [Related]
56. Castleman Disease Pathogenesis.
Fajgenbaum DC; Shilling D
Hematol Oncol Clin North Am; 2018 Feb; 32(1):11-21. PubMed ID: 29157613
[TBL] [Abstract][Full Text] [Related]
57. International definition of iMCD-TAFRO: future perspectives.
Nishimura Y; Nishimura MF; Sato Y
J Clin Exp Hematop; 2022 Jun; 62(2):73-78. PubMed ID: 35474036
[TBL] [Abstract][Full Text] [Related]
58. Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease.
Marcelin AG; Motol J; Guihot A; Caumes E; Viard JP; Dussaix E; Cadranel J; Frances C; Carcelain G; Calvez V; Dupin N
J Infect Dis; 2007 Oct; 196(8):1163-6. PubMed ID: 17955434
[TBL] [Abstract][Full Text] [Related]
59. Deconstructing the liquid architecture of human herpesvirus 8 diseases.
Polizzotto MN
Br J Haematol; 2023 Feb; 200(4):401-403. PubMed ID: 36397674
[TBL] [Abstract][Full Text] [Related]
60. Pathological Features of Kaposi's Sarcoma-Associated Herpesvirus Infection.
Katano H
Adv Exp Med Biol; 2018; 1045():357-376. PubMed ID: 29896675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
